- Trial phase
- Phase 2
- Time to market
- Praliciguat is in Phase 2 testing with estimated trial completion in January 2028. If successful, a Phase 3 program would be needed before any FDA submission, placing potential approval several years away at best.
- Why 3/10
- Praliciguat has no scheduled binary catalyst within the next ~12 months. The Phase 2 FSGS trial is still enrolling with estimated completion in January 2028, and management provided no data readout timeline on the Q3 2026 earnings call. The drug is a small, early-stage pipeline component; Akebia's primary value driver is its approved anemia drug Vafseo (vadadustat).
Praliciguat has no near-term binary catalyst. The Phase 2 FSGS trial is still enrolling with estimated completion in January 2028, and Akebia's Q3 2026 earnings call provided no data timeline for this asset. Watch for any future update on enrollment completion or a topline data readout timeline, but praliciguat is unlikely to be a meaningful stock-moving catalyst for AKBA in the next 12 months. The stock's near-term drivers are Vafseo commercial execution and the Nasdaq minimum bid price compliance situation.
Price Chart
Executive Summary
Praliciguat (IW-1973) is an oral, once-daily soluble guanylate cyclase (sGC) stimulator being developed by Akebia Therapeutics (NASDAQ: AKBA) for focal segmental glomerulosclerosis (FSGS), a rare kidney disease with no FDA-approved therapies. Akebia licensed the drug from Cyclerion Therapeutics in 2021 after prior Phase 2 studies in heart failure and diabetic kidney disease showed no clear clinical benefit. The drug is currently in a Phase 2 trial (NCT07268638) that began enrolling in December 2025, with first patient dosed in January 2026 and estimated completion in January 2028. Akebia presented a trial-in-progress poster at ASN Kidney Week in October 2026. Praliciguat is a small, early-stage pipeline component for Akebia; the company's primary value driver is its approved anemia drug Vafseo (vadadustat). No data readout timeline has been provided for praliciguat.
How It Works
Praliciguat is a small molecule that stimulates an enzyme called soluble guanylate cyclase (sGC), which amplifies the body's natural nitric oxide signaling pathway. This pathway helps blood vessels relax, reduces inflammation, and protects kidney cells from injury. By boosting this signaling, the drug aims to reduce protein leakage in the urine and preserve kidney function in patients with FSGS, a rare kidney disease where the filtering units of the kidney are scarred.
Trial Status
Praliciguat is in a Phase 2, randomized, double-blind, placebo-controlled, multicenter trial (NCT07268638) for focal segmental glomerulosclerosis (FSGS). The trial aims to enroll approximately 60 patients who are randomized 1:1 to praliciguat or placebo for a 24-week treatment period, followed by an open-label extension. The primary endpoint is change in urine protein-to-creatinine ratio. The trial began in December 2025, with first patient dosed in January 2026. As of the Q3 2026 earnings call (November 5, 2026), the company confirmed the trial is enrolling but provided no data readout timeline. Estimated primary completion is January 2028. Akebia presented a trial-in-progress poster at ASN Kidney Week in October 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 FSGS trial enrollment completion update (no timeline provided)
- Potential future topline data readout from Phase 2 FSGS trial (estimated trial completion January 2028, no specific data timeline announced)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Akebia Therapeutics, Inc. PRESS-RELEASE AKBA ·Originating report